MiTeGen Announces Mutual Distribution Agreements with Rigaku Reagents
News Jul 25, 2015
MiTeGen LLC has announced that it has signed mutual distribution agreements with Rigaku Reagents.
“This is a very synergistic partnership for both companies, and we are pleased to expand our product offerings to Rigaku Reagents customers to include MiTeGen products." says Angela Criswell, VP, Life Science X-ray Products, Rigaku Americas Corporation.
Criswell continued, “We also welcome the additional distribution channels for MiTeGen to offer our Wizard Screens and other products. Having MiTeGen as a partner will help ensure that we are able to offer a broad range of product solutions to our customers.
Under the agreements, Rigaku Reagents will promote and sell MiTeGen’s products for crystallization, crystal harvesting, data collection, and other MiTeGen product lines world-wide. These will include products such as MiTeGen's In Situ-1 crystallization plates, MicroMounts™ & MicroLoops™, Reusable Bases, MicroRT™ system and more. MiTeGen will promote and sell the Wizard product lines of matrix screens and other Rigaku Reagent products lines in the US.
Customers can now order Rigaku Reagent products through MiTeGen, and will be able to order MiTeGen products through Rigaku Reagents within the coming month.
“We have had a longstanding and mutually beneficial relationship with Rigaku Corporation in Japan, and are very pleased to expand our partnership with this important agreement with Rigaku Reagents” says Robert Newman, CEO of MiTeGen. “I am sure our customers will be glad to see the addition of the Wizard screens and other great Rigaku Reagents products to our catalog. They will also benefit from the ease of ordering desired products from either vendor.”
New Opportunities for Type 2 Diabetes Drug Discovery: Researchers Determine Glucagon Receptor StructureNews
Complex structure of a class B GPCR bound to an analogue of its endogenous ligand ignites new excitement in GPCR research.READ MORE
Innovative ALS Therapy Startup Wins Golden Ticket Funding From AmgenNews
Amgen and LabCentral have announced that Kernal Biologics Inc. and QurAlis have won the Amgen Golden Ticket at LabCentral.READ MORE
MiNT Protein: A New Target to Treat Cancer, Diabetes and Other Diseases?News
A two-faced protein in a chain that regulates iron and other elements in cells could provide a new target to treat cancer, diabetes and other diseases.READ MORE